Goldman Sachs’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-385,798
| Closed | -$12.9M | – | 6955 |
|
|
2026
Q1 | $12.9M | Sell |
385,798
-527,252
| -58% | -$20.7M | ﹤0.01% | 2842 |
|
|
2025
Q4 | $42.3M | Buy |
913,050
+357,612
| +64% | +$19.6M | 0.01% | 1652 |
|
|
2025
Q3 | $37.5M | Buy |
555,438
+210,466
| +61% | +$15.6M | ﹤0.01% | 1665 |
|
|
2025
Q2 | $28.9M | Sell |
344,972
-288,138
| -46% | -$21.6M | ﹤0.01% | 1793 |
|
|
2025
Q1 | $45.2M | Buy |
633,110
+213,667
| +51% | +$10.4M | 0.01% | 1301 |
|
|
2024
Q4 | $18.9M | Buy |
419,443
+56,293
| +16% | +$2.92M | ﹤0.01% | 2188 |
|
|
2024
Q3 | $18.3M | Buy |
363,150
+162,112
| +81% | +$7.76M | ﹤0.01% | 2147 |
|
|
2024
Q2 | $8.2M | Sell |
201,038
-10,879
| -5% | -$461K | ﹤0.01% | 2702 |
|
|
2024
Q1 | $9.07M | Buy |
211,917
+143,318
| +209% | +$6.48M | ﹤0.01% | 2553 |
|
|
2023
Q4 | $2.76M | Buy |
+68,599
| New | +$1.95M | ﹤0.01% | 3671 |
|
|
2021
Q3 | – | Sell |
-7,292
| Closed | -$124K | – | 6486 |
|
|
2021
Q2 | $124K | Buy |
7,292
+3,354
| +85% | +$56.7K | ﹤0.01% | 5892 |
|
|
2021
Q1 | $74K | Sell |
3,938
-867
| -18% | -$27.9K | ﹤0.01% | 5893 |
|
|
2020
Q4 | $139K | Sell |
4,805
-15,145
| -76% | -$437K | ﹤0.01% | 5215 |
|
|
2020
Q3 | $751K | Buy |
+19,950
| New | +$583K | ﹤0.01% | 4262 |
|
|
2020
Q2 | – | Sell |
-2,622
| Closed | -$94K | – | 5455 |
|
|
2020
Q1 | $94K | Buy |
+2,622
| New | +$112K | ﹤0.01% | 4951 |
|
|
2017
Q4 | – | Sell |
-136
| Closed | -$5K | – | 6620 |
|
|
2017
Q3 | $5K | Sell |
136
-250
| -65% | -$9.86K | ﹤0.01% | 6574 |
|
|
2017
Q2 | $15K | Hold |
386
| – | – | ﹤0.01% | 6603 |
|
|
2017
Q1 | $21K | Buy |
386
+66
| +21% | +$3.89K | ﹤0.01% | 6502 |
|
|
2016
Q4 | $19K | Sell |
320
-31
| -9% | -$2.15K | ﹤0.01% | 6658 |
|
|
2016
Q3 | $24K | Buy |
+351
| New | +$26.6K | ﹤0.01% | 6702 |
|
Goldman Sachs's SLNO Position: Q2 2026 in Review
Goldman Sachs sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 385,798 shares — an estimated $12.9M sold.
Goldman Sachs first reported a position in SLNO in Q3 2016 and held it in 20 quarters. The position peaked at $45.2M in Q1 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Goldman Sachs reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Goldman Sachs sold 385,798 Soleno Therapeutics shares in Q2 2026, an estimated $12.9M.
- Goldman Sachs first reported a position in Soleno Therapeutics in Q3 2016 and held it in 20 quarters.
- Goldman Sachs's Soleno Therapeutics position peaked at $45.2M in Q1 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.